CD95L/Fas ligand selective inhibition: Rationale and clinical results

Date 30 September 2019
Event ESMO 2019 Congress
Session ESMO Colloquium supported by Apogenix - Recurrent glioblastoma management: Challenges and opportunities
Topics Basic Scientific Principles
Biological Therapy
Central Nervous System Malignancies
Presenter Wolfgang Wick
Authors W. Wick
  • University of Heidelberg, 69120 - Heidelberg/DE